CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 100 target
Drug / intervention
MRG002drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05141786
NCT05141786Phase 2Unknown
CompareCT.gov

An Open-label, Multi-center, Non-randomized Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Shanghai Miracogen Inc.·interventional·Posted Dec 2, 2021·Updated Dec 2, 2021

In Brief

A Phase 2 clinical trial evaluating MRG002 for Non-small- Cell Lung Cancer (NSCLC). Targeting 100 participants across 1 site.

Detailed Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-mutated unresectable or metastatic non-small-cell lung cancer (NSCLC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small- Cell Lung Cancer (NSCLC)
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20222023202420252026
First PostedDec 2, 2021
Enrollment StartDec 1, 2021
Primary CompletionDec 1, 2023
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 4.6 years ago

Interventions

MRG002drug

Administrated intravenously